New Evidence Fuels Concerns About The Safety Of Niacin

The string of failures-- for HDL therapies in general and for niacin in particular-- continues unabated.  The publication of the main results of the HPS2-THRIVE trial, along with new information from the AIM-HIGH trial, provide no evidence of a beneficial effect for niacin but do fuel concerns that it may cause serious adverse effects.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news